<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[0, 8] Systemic hemodynamic, neurohormonal, and renal effects<br>[51, 59] systemic hemodynamic, neurohormonal, and renal effects<br>[171, 174] adverse events.<br>[182, 185] right atrial pressure<br>[186, 190] pulmonary capillary wedge pressure<br>[204, 207] systemic vascular resistance<br>[233, 235] cardiac index<br>[244, 247] heart rate.<br>[251, 252] hBNP<br>[253, 260] plasma norepinephrine and aldosterone. Renal hemodynamics<br>[290, 297] cardiac preload and systemic vascular resistance.<br>[302, 304] cardiac output<br>[306, 309] heart rate.<br>[311, 316] Plasma norepinephrine and aldosterone levels<br></td>
<td width=33%>
[0, 8] Systemic hemodynamic, neurohormonal, and renal effects<br>[51, 59] systemic hemodynamic, neurohormonal, and renal effects<br>[171, 174] adverse events.<br>[182, 185] right atrial pressure<br>[186, 190] pulmonary capillary wedge pressure<br>[204, 207] systemic vascular resistance<br>[233, 235] cardiac index<br>[244, 247] heart rate.<br>[251, 252] hBNP<br>[253, 258] plasma norepinephrine and aldosterone.<br>[258, 260] Renal hemodynamics<br>[290, 297] cardiac preload and systemic vascular resistance.<br>[302, 304] cardiac output<br>[306, 309] heart rate.<br>[311, 316] Plasma norepinephrine and aldosterone levels<br></td>
<td width=33%>
[0, 8] Systemic hemodynamic, neurohormonal, and renal effects<br>[45, 48] cardiac failure.<br>[51, 59] systemic hemodynamic, neurohormonal, and renal effects<br>[143, 146] Urinary volume losses<br>[171, 174] adverse events.<br>[181, 190] reduced right atrial pressure and pulmonary capillary wedge pressure<br>[202, 207] significantly lowered systemic vascular resistance<br>[231, 235] increase in cardiac index<br>[241, 247] no change in heart rate.<br>[251, 258] hBNP decreased plasma norepinephrine and aldosterone.<br>[258, 260] Renal hemodynamics<br>[270, 276] resistant to its natriuretic effect.<br>[282, 284] hemodynamic effects<br>[290, 297] cardiac preload and systemic vascular resistance.<br>[302, 309] cardiac output without increasing heart rate.<br>[311, 316] Plasma norepinephrine and aldosterone levels<br>[325, 334] pharmacologically active and has potential in the therapy for<br>[335, 338] heart failure.<br></td>
</tr>
